In the largest investment into US pharmaceutical manufacturing to date, Eli Lilly will expand its domestic medicine manufacturing capabilities with four new production sites.
Three of the sites will manufacture active pharmaceutical ingredients (APIs), while one will bolster the company's parenteral manufacturing network for the production of next-generation injectable therapies.
This announcement, which was made at a press conference in Washington D.C., follows the company's previous investment into its US manufacturing capacity — with $50bn being spent on expansions since 2020.
Through this expansion, Eli Lilly will create more than 3,000 skilled roles for workers across the US, with engineering, scientist, operations and lab technician positions all required.
The expansion will also enhance the US' standing as a global pharmaceutical manufacturing hub, increasing the country's infrastructure in this key market.
This follows the Trump Administration's call to Big Pharma, requiring companies in this space to reshore manufacturing operations or face high tariffs.
"Our confidence in the potential of our drug pipeline positions us to help reinvigorate domestic manufacturing, which will benefit hard-working American families and increase exports of medicines made in the US," noted Chair and CEO of Lilly, David A. Ricks.
"This bold move reflects our commitment to stay ahead of anticipated demand for safe, high-quality, FDA-approved medicines of the future."
"To deliver on our big bets on next-generation modalities like small molecules, biologics and nucleic acid therapies, Lilly is investing in the manufacturing infrastructure needed to deliver tomorrow's safe and reliable medicines," said Executive VP and President of Lilly Manufacturing Operations, Edgardo Hernandez.
"We are not just building facilities. We are creating a future where American innovation leads the world in pharmaceutical manufacturing, requiring a highly skilled workforce prepared to shape the future of health care. This is a significant step for our company, our communities and the patients we serve."
Eli Lilly is currently in negotiations with several states, and is open to interest until March 12, 2025.